Johnson & Johnson Sells Off Ahead of Earnings: Time to Cut Losses or Double Down?
Investing.com | Apr 11, 2024 14:44
- Despite bullish markets, Johnson & Johnson's stock price has declined over 4% year-to-date.
- Attention has now turned to the upcoming acquisition of Shockwave.
- Investors eagerly anticipate next week's earnings for insights into Johnson & Johnson's performance.
- In 2024, invest like the big funds from the comfort of your home with our AI-powered ProPicks stock selection tool.
- ProPicks: AI-managed portfolios of stocks with proven performance.
- ProTips: digestible information to simplify a lot of complex financial data into a few words.
- Advanced Stock Finder: Search for the best stocks based on your expectations, taking into account hundreds of financial metrics.
- Historical financial data for thousands of stocks: So that fundamental analysis professionals can delve into all the details themselves.
- And many other services, not to mention those we plan to add in the near future.
Despite the widespread bull market since the beginning of the year, Johnson & Johnson's (NYSE:JNJ) stock has continually disappointed investors.
To break free from the downward spiral, the Pharma giant has recently stepped on the gas in its acquisition strategy in the medical market. The company's latest target is Shockwave, a specialist in cardiovascular therapy technology.
Investor attention is now turning to the upcoming quarterly results, set to be published next Tuesday. These results present an opportunity for Johnson & Johnson stock to reverse the downtrend, provided the number exceeds forecasts.
Otherwise, given yesterday's U.S. inflation data, which isn't favorable for stock markets, we may see the bears testing last year's lows formed in November.
h2 Expanding Influence in the MedTech Segment/h2After recent acquisitions like Abiomed (NASDAQ:ABMD) and Laminar, Johnson & Johnson is now finalizing its $13.1 billion purchase of Shockwave.
This company specializes in therapies to break down calcification in arteries, reducing the risk of heart attacks. This move aims to diversify J&J's business and expand its portfolio, especially considering the looming threat of losing patent protection for the drug Stelar, which generates significant annual revenue.
One concern is whether this extensive spending on acquisitions will affect dividend payments, a fundamental aspect of Johnson & Johnson's appeal. However, with a history of over 50 years of dividend payments and a high coverage ratio of interest payments, the risk of a significant decline in dividend payouts is limited.
Source: InvestingPro
h2 What to Expect From Johnson and Johnson's Upcoming Earnings?/h2The following consensus will be the benchmark for market reaction:
Get The App
Source: InvestingPro
If the final readings match forecasts, it will mean a decrease from last year's figures, when earnings per share stood at $2.68 and revenues reached $24.746 billion. This negative outlook contributes to the ongoing selling pressure on the stock.
h2 Technical View: Downtrend to Continue?/h2The downward trend that started last month continues, with a high probability of dipping below the $150 per share mark. If sellers succeed in this move, the primary scenario is to target last year's lows of around $145 per share.
If the quarterly results beat forecasts, there's a chance for a rebound, aiming first for around $158 per share. Breaking above the tough resistance at $163 would signal a potential shift in trend.
***
Want to try the tools that maximize your portfolio? Take advantage .
Use the code and get almost 40% off your 1-year subscription - less than what a Netflix (NASDAQ:NFLX) subscription costs you! (And you get more out of your investments too). With it you'll get:
Act fast and join the investment revolution - get your OFFER HERE !
Disclaimer: The author does not own any of these shares. This content, which is prepared for purely educational purposes, cannot be considered as investment advice.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.